Cargando…
Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
PURPOSE: Aclidinium–formoterol 400/12 µg is a long-acting muscarinic antagonist (LAMA) and a long-acting β(2)-agonist in a fixed-dose combination used in the management of patients with COPD. This study aimed to assess the cost-effectiveness of aclidinium–formoterol 400/12 µg against the long-acting...
Autores principales: | Ramos, Mafalda, Haughney, John, Henry, Nathaniel, Lindner, Leandro, Lamotte, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026215/ https://www.ncbi.nlm.nih.gov/pubmed/27672337 http://dx.doi.org/10.2147/CEOR.S107121 |
Ejemplares similares
-
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
por: D’Urzo, Anthony D, et al.
Publicado: (2019) -
Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
por: D’Urzo, Anthony D., et al.
Publicado: (2019) -
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022) -
Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
por: Moitra, Subhabrata, et al.
Publicado: (2015) -
Folate Status of Reproductive Age Women and Neural Tube Defect Risk: The Effect of Long-Term Folic Acid Supplementation at Doses of 140 µg and 400 µg per Day
por: Hursthouse, Nicola A., et al.
Publicado: (2011)